Major trial tests new shot to protect seniors from dangerous RSV lung infections
⭐️ VACCINE ⭐️
Recruiting now
This large, late-stage study is testing a new vaccine designed to protect adults aged 60 and older from serious lung diseases caused by Respiratory Syncytial Virus (RSV). About 25,000 participants will receive either the single-dose vaccine or a placebo to see if it safely preven…
Phase: PHASE3 • Sponsor: MAXVAX Biotechnology Limited Liability Company • Aim: ⭐️ VACCINE ⭐️
Last updated Mar 25, 2026 14:09 UTC